{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+400&page=36", "query": { "intervention": "Combination 400", "page": 36 }, "page_size": 10 }, "pagination": { "page": 36, "page_size": 10, "total_count": 1062, "total_pages": 107, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+400&page=37&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+400&page=35&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-10T00:06:20.971Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00673673", "title": "FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastroesophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "FOLFOX", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2008-05", "completion_date": "2014-07", "has_results": true, "last_update_posted_date": "2015-02-04", "last_synced_at": "2026-11-10T00:06:20.971Z", "location_count": 2, "location_summary": "Hamden, Connecticut • New Haven, Connecticut", "locations": [ { "city": "Hamden", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00673673" }, { "nct_id": "NCT01004731", "title": "Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Stage IV Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Cetuximab in combination with Carboplatin/Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2001-06", "completion_date": "2006-01", "has_results": false, "last_update_posted_date": "2023-05-25", "last_synced_at": "2026-11-10T00:06:20.971Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01004731" }, { "nct_id": "NCT03217838", "title": "Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukaemia" ], "interventions": [ { "name": "AZD2811", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 50, "start_date": "2017-07-31", "completion_date": "2021-03-25", "has_results": false, "last_update_posted_date": "2022-04-05", "last_synced_at": "2026-11-10T00:06:20.971Z", "location_count": 10, "location_summary": "Denver, Colorado • Sarasota, Florida • Detroit, Michigan + 7 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Canton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03217838" }, { "nct_id": "NCT00308516", "title": "5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rectal Cancer", "Cancer of the Rectum", "Colorectal Cancer" ], "interventions": [ { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "PROCEDURE" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2006-03", "completion_date": "2012-02", "has_results": true, "last_update_posted_date": "2021-12-10", "last_synced_at": "2026-11-10T00:06:20.971Z", "location_count": 14, "location_summary": "Anniston, Alabama • Jonesboro, Arkansas • Fort Myers, Florida + 11 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Lakeland", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00308516" }, { "nct_id": "NCT00890305", "title": "Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "CT-011", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medivation, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 171, "start_date": "2009-05", "completion_date": "2013-03", "has_results": false, "last_update_posted_date": "2015-07-08", "last_synced_at": "2026-11-10T00:06:20.971Z", "location_count": 5, "location_summary": "Huntsville, Alabama • Tampa, Florida • New York, New York + 2 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Tampa", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "Middletown", "state": "Ohio" }, { "city": "Lubbock", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00890305" }, { "nct_id": "NCT04777851", "title": "Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Hepatocellular" ], "interventions": [ { "name": "Regorafenib in combination with pembrolizumab", "type": "DRUG" }, { "name": "Loco-regional therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Translational Research in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2023-10-11", "completion_date": "2026-02-26", "has_results": false, "last_update_posted_date": "2026-03-09", "last_synced_at": "2026-11-10T00:06:20.971Z", "location_count": 1, "location_summary": "Santa Monica, California", "locations": [ { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04777851" }, { "nct_id": "NCT00901901", "title": "Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Hepatocellular" ], "interventions": [ { "name": "Sorafenib (Nexavar, BAY43-9006)", "type": "DRUG" }, { "name": "Erlotinib (Tarceva)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 732, "start_date": "2009-05-21", "completion_date": "2018-05-23", "has_results": true, "last_update_posted_date": "2019-05-30", "last_synced_at": "2026-11-10T00:06:20.971Z", "location_count": 23, "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Gainesville, Florida + 19 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00901901" }, { "nct_id": "NCT01808144", "title": "Lesinurad and Febuxostat Combination Extension Study in Gout", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gout" ], "interventions": [ { "name": "lesinurad", "type": "DRUG" }, { "name": "febuxostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ardea Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 196, "start_date": "2013-03-01", "completion_date": "2016-10-06", "has_results": true, "last_update_posted_date": "2018-01-30", "last_synced_at": "2026-11-10T00:06:20.971Z", "location_count": 55, "location_summary": "Birmingham, Alabama • Tempe, Arizona • Glendale, California + 50 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Glendale", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01808144" }, { "nct_id": "NCT05827081", "title": "Phase IIIb Study of Ribociclib + ET in Early Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Early Breast Cancer" ], "interventions": [ { "name": "Ribociclib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Ansastrozole", "type": "DRUG" }, { "name": "Goserelin", "type": "DRUG" }, { "name": "Leuprolide", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 1466, "start_date": "2024-02-28", "completion_date": "2030-09-20", "has_results": false, "last_update_posted_date": "2026-11-03", "last_synced_at": "2026-11-10T00:06:20.971Z", "location_count": 79, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 69 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05827081" }, { "nct_id": "NCT00343291", "title": "A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 121, "start_date": "2006-12", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2011-06-07", "last_synced_at": "2026-11-10T00:06:20.971Z", "location_count": 43, "location_summary": "Decatur, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 39 more", "locations": [ { "city": "Decatur", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Grass Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00343291" } ] }